We have identified fusion mRNAs (PRKAA-TTC33, SAMM50-PARVB, P2RX5-TAX1BP3, URB1-C21ORF45, CTBS-GNG5, CHD2-CHMP1A, ADK-DHX8), that are expressed by human cells and tissues. Among them, we have shown that the PRKAA-TTC33, SAMM50-PARVB, CHD2-CHMP1A chimeras stimulate the growth of tumor cells. This makes these chimeras effective therapeutic targets, that we have exploited to develop new efficient anti-tumor tools. The invention here presented concerns the chimeric mRNAs that stimulate tumor growth (PRKAATTC33, SAMM50-PARVB, CHD2-CHMP1A); the methods used to reveal their presence and to quantify the levels of these fusion RNAs; the use of these fusion RNAs as a target of antitumor therapy; the methods used to inhibit the expression of these fusion RNAs in cells and tissues.
Oligonucleotide sequences that inhibit the expression of chimeric mRNA that control the growth of tumor cells and their use in the medical field
alberti Saverio
Conceptualization
2012-01-01
Abstract
We have identified fusion mRNAs (PRKAA-TTC33, SAMM50-PARVB, P2RX5-TAX1BP3, URB1-C21ORF45, CTBS-GNG5, CHD2-CHMP1A, ADK-DHX8), that are expressed by human cells and tissues. Among them, we have shown that the PRKAA-TTC33, SAMM50-PARVB, CHD2-CHMP1A chimeras stimulate the growth of tumor cells. This makes these chimeras effective therapeutic targets, that we have exploited to develop new efficient anti-tumor tools. The invention here presented concerns the chimeric mRNAs that stimulate tumor growth (PRKAATTC33, SAMM50-PARVB, CHD2-CHMP1A); the methods used to reveal their presence and to quantify the levels of these fusion RNAs; the use of these fusion RNAs as a target of antitumor therapy; the methods used to inhibit the expression of these fusion RNAs in cells and tissues.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
